RMD - Haemonetics Banks on Growing Plasma Arm Innovation | Benzinga
Haemonetics (NYSE: HAE) has been gaining from business growth within Plasma, Hospital and Hemostasis Management. Its new launches also aid growth. The stock carries a Zacks Rank #1 (Strong Buy) currently.
Haemonetics' Plasma revenues grew 6% in the fourth quarter of fiscal 2024, driven primarily by disposable volume and software. The collections environment in the United States continued to be favorable, with disposables growing 4% in the quarter and 13% in fiscal 2024.
The company is gaining from the newly-completed limited market release of the new Express Plus technology with more than 60,000 real-world collections. Haemonetics is currently initiating the full-market release of the new Express Plus technology in the United States. This technology is fast gaining new customers.
The rollout of Persona — the company's proprietary technology proven to increase yield from 9% to 12% on average — continues to gain momentum, with more than 25 million collections.
Advancements in NexLynk DMS (Donor Management System), its bidirectional connectivity software, are improving cycle times, reducing errors and allowing staff to focus on taking care of donors and reducing door-to-door time, a key determinant of donor satisfaction. The combination of Persona, Express Plus and NexLynk sets a new industry standard for center throughput, cost per liter and donor satisfaction. According to Haemonetics, NexSys with Persona remains unrivaled in enabling collectors to safely meet end-market demand and lower cost per liter. The company is currently putting efforts to enhance the NexSys platform, expanding its competitive advantage as the global industry standard for plasma collection.